Capricor TherapeuticsCAPR Market cap $765M
About: Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
Employees: 102
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
29% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 17
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
9% more funds holding
Funds holding: 56 [Q1] → 61 (+5) [Q2]
4.39% more ownership
Funds ownership: 15.7% [Q1] → 20.1% (+4.39%) [Q2]
8% less capital invested
Capital invested by funds: $33.5M [Q1] → $30.7M (-$2.82M) [Q2]
26% less call options, than puts
Call options by funds: $1.36M | Put options by funds: $1.84M
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
8 analyst ratings
Oppenheimer Leland Gershell 58% 1-year accuracy 32 / 55 met price target | 99%upside $43 | Outperform Maintained | 25 Sept 2024 |
Maxim Group Jason McCarthy 35% 1-year accuracy 7 / 20 met price target | 15%upside $25 | Buy Maintained | 25 Sept 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 87 / 281 met price target | 85%upside $40 | Buy Reiterated | 24 Sept 2024 |
Oppenheimer Leland Gershell 58% 1-year accuracy 32 / 55 met price target | 31%downside $15 | Outperform Reiterated | 23 Sept 2024 |
Cantor Fitzgerald Kristen Kluska 51% 1-year accuracy 50 / 99 met price target | 63%downside $8 | Overweight Reiterated | 20 Sept 2024 |
Financial journalist opinion
Based on 9 articles about CAPR published over the past 30 days